| Dr Marshall Edward Mccabe Iii, MD | |
|
406 Black Hills Ln Sw, Ste A, Olympia, WA 98502-8144 | |
| (360) 754-1735 | |
| (360) 704-3404 |
| Full Name | Dr Marshall Edward Mccabe Iii |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 46 Years |
| Location | 406 Black Hills Ln Sw, Olympia, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831191162 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD00023393 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Centralia Hospital | Centralia, WA | Hospital |
| Grays Harbor Community Hospital | Aberdeen, WA | Hospital |
| Capital Medical Center | Olympia, WA | Hospital |
| Providence St Peter Hospital | Olympia, WA | Hospital |
| Mason General Hospital & Family Of Clinics | Shelton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Olympia Multi Specialty Clinic | 4789571092 | 18 |
News Archive
Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
The GSMA today published research that demonstrates the significant socio-economic impact that mHealth adoption will have in Europe. Findings reveal that mHealth could save almost €100 billion in healthcare costs in the EU by 2017 as well as add €93 billion in GDP.
The coupling of molecular building blocks nearly as easy as "snapping" them together can be realized by means of the "click chemistry" tool kit. American scientists have now introduced another achievement for the click concept in the journal Angewandte Chemie: the sulfur fluoride exchange reaction (SuFEx) can be used to form robust inorganic bridges between carbon centers and opens up a fully unexplored area of chemistry with countless new molecules that could form the basis for new drugs, diagnostics, plastics, "intelligent" materials, and many other products.
A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect (ASD). The BioSTAR device displayed successful outcomes, while avoiding issues associated with implants containing substantial amounts of metal.
› Verified 9 days ago
| Entity Name | Olympia Multi Specialty Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356386783 PECOS PAC ID: 4789571092 Enrollment ID: O20040302000502 |
News Archive
Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
The GSMA today published research that demonstrates the significant socio-economic impact that mHealth adoption will have in Europe. Findings reveal that mHealth could save almost €100 billion in healthcare costs in the EU by 2017 as well as add €93 billion in GDP.
The coupling of molecular building blocks nearly as easy as "snapping" them together can be realized by means of the "click chemistry" tool kit. American scientists have now introduced another achievement for the click concept in the journal Angewandte Chemie: the sulfur fluoride exchange reaction (SuFEx) can be used to form robust inorganic bridges between carbon centers and opens up a fully unexplored area of chemistry with countless new molecules that could form the basis for new drugs, diagnostics, plastics, "intelligent" materials, and many other products.
A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect (ASD). The BioSTAR device displayed successful outcomes, while avoiding issues associated with implants containing substantial amounts of metal.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marshall Edward Mccabe Iii, MD 406 Black Hills Ln Sw, Ste A, Olympia, WA 98502-8144 Ph: (360) 754-1735 | Dr Marshall Edward Mccabe Iii, MD 406 Black Hills Ln Sw, Ste A, Olympia, WA 98502-8144 Ph: (360) 754-1735 |
News Archive
Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.
The GSMA today published research that demonstrates the significant socio-economic impact that mHealth adoption will have in Europe. Findings reveal that mHealth could save almost €100 billion in healthcare costs in the EU by 2017 as well as add €93 billion in GDP.
The coupling of molecular building blocks nearly as easy as "snapping" them together can be realized by means of the "click chemistry" tool kit. American scientists have now introduced another achievement for the click concept in the journal Angewandte Chemie: the sulfur fluoride exchange reaction (SuFEx) can be used to form robust inorganic bridges between carbon centers and opens up a fully unexplored area of chemistry with countless new molecules that could form the basis for new drugs, diagnostics, plastics, "intelligent" materials, and many other products.
A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect (ASD). The BioSTAR device displayed successful outcomes, while avoiding issues associated with implants containing substantial amounts of metal.
› Verified 9 days ago
Miss Tui Agaapapalagi Lauilefue, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3920 Capital Mall Dr Sw Ste 200, Olympia, WA 98502 Phone: 360-596-4899 Fax: 360-596-4889 | |
Monique C. Semien, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 Fax: 360-923-7089 | |
Colleen M Overdorf, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 500 Lilly Rd Ne Ste 201, Olympia, WA 98506 Phone: 360-413-8272 | |
Dr. Philip William Berger, D.O. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 406 Black Hills Ln Sw, Ste A, Olympia, WA 98502 Phone: 360-754-1737 Fax: 360-704-3408 | |
Mr. Robert Love Huck, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 500 Lilly Rd Ne Suite 201, Olympia, WA 98503 Phone: 360-413-8272 Fax: 360-413-8878 | |
Dr. Ngozi Achebe, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3900 Capitol Mall Dr Sw, Sw, Olympia, WA 98502 Phone: 360-754-5858 Fax: 360-704-4751 | |
Dr. Robert C Tomford, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 500 Lilly Rd Ne, Suite 203, Olympia, WA 98506 Phone: 360-413-8121 Fax: 360-413-8865 |